Table 2 Prostate-specific antigen (PSA) response rate and progression-free survival (PFS) and overall survival (OS) according to Grade Group 2–4 versus Grade Group 5 and treatment.

From: Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

First line mCRPC

Docetaxel

p value

Abiraterone or enzalutamide

p value

Grade group 2–4

Grade group 5

Grade group 2–4

Grade group 5

PSA response rate (%)

44 (72.1)

20 (62.5)

0.34

62 (72.1)

20 (66.7)

0.57

Median PFS, months (95% CI)

10.6 (8.9–11.5)

9.0 (7.3–10.9)

0.55

16.6 (11.9–18.7)

10.8 (7.8–17.6)

0.22

Median OS, months (95% CI)

37.6 (30.5–48.2)

29.8 (22.2–46.7)

0.09

29.8 (27.1–50.5)

44.2 (20.7–52.8)

0.69

  1. PSA Prostate-specific antigen, PFS Progression-free survival, OS Overall survival, mCRPC metastatic castration-resistant prostate cancer, nr not reached.
Back to article page